Save on Tepylute with Coupons, Discounts & Savings Programs

Tepylute (thiotepa) is an IV infusion used to treat certain breast and ovarian cancers.

Tepylute is available as a 15 mg/1.5 mL (10 mg/mL) solution in single dose vial.

Tepylute is an alkylating drug that is approved for the treatment of patients with breast cancer (BC) or ovarian cancer (OC).

Tepylute is an alkylating agent that works by attaching to a DNA stand on the cancer cell, preventing them from growing and spreading.

The recommended dose of Tepylute is 0.3 mg/kg to 0.4 mg/kg given intravenously. Your dose may be adjusted based on how well it works and how you tolerate it.

Tepylute is a safe and effective treatment when used for FDA approved indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not take this medication if you are allergic to thiotepa or any inactive ingredients in the product. You should not take this medication along with live vaccines.

Common side effects of Tepylute: Bleeding gums Blood in the urine Blurred or double vision Confusion Coughing up blood Cracked lips Diarrhea Difficulty with breathing or swallowing Difficulty with walking Dizziness Drooping eyelids Headache Increased menstrual flow or Vaginal bleeding Jaw pain Nausea and vomiting

Serious side effects are rare with Tepylute. Contact your healthcare provider immediately if you experience any of the following: Serious allergic reactions, including anaphylaxis: rash, itching, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after receiving this medicine Skin reactions: skin discoloration, itching, blistering or peeling skin in the groin, underarms, skin folds, in the neck, and under dressings Liver problems: bloated abdomen or stomach, pain in the upper right abdomen, or yellow skin or eyes

The following medications may interact with Tepylute: CYP3A4 inhibitors: Avoid using strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with Tepylute Strong CYP3A4 modulators: Closely monitor for adverse drug reactions

Shorla Oncology

Tepylute may cause harm to your unborn baby. Females should use effective contraception during treatment with Tepylute and for 6 months after the last dose. Males should use effective contraception during Tepytlute treatment and for 1 year after their last dose.

• Thiotepa